Eli Lilly and Company India has launched Tanstrive, a targeted cancer treatment designed for patients with locally advanced or metastatic solid tumours driven by RET gene alterations. The drug expands the use of precision oncology in India, where treatment is increasingly tailored to genetic mutations rather than only tumour location.
Regulatory Approval and Launch
The company introduced the drug after receiving marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO). Tanstrive aims to improve treatment outcomes by specifically targeting abnormal cancer-driving pathways linked to RET alterations.
How the Drug Works
Tanstrive works as a RET inhibitor and blocks abnormal signalling pathways that promote tumour growth. Additionally, it is an oral therapy taken twice daily, making it more convenient compared to several hospital-based cancer treatments. The therapy is intended only for patients whose tumours test positive for RET gene alterations through genomic testing.
Dosage and Pricing
The drug is available in tablet strengths of 40 mg, 80 mg, 120 mg, and 160 mg. Moreover, it is priced at ₹2.15 lakh per box, which covers a 14-day treatment cycle.
Growing Role of Precision Oncology
As reported by Business Today, the launch reflects the growing shift toward precision medicine in India’s oncology landscape. In particular, targeted therapies like Tanstrive are expected to support patients with limited treatment options, especially in advanced-stage cancers.
Industry Perspective
Eli Lilly stated that the treatment strengthens access to next-generation cancer therapies in India. As per Business Today, the company highlighted that Tanstrive represents an important step forward in expanding precision oncology options for patients with RET-driven cancers.
Outlook
However, despite its clinical promise, affordability may remain a challenge due to the high treatment cost. Consequently, insurance coverage, reimbursement mechanisms, and patient assistance programs will likely influence how widely the drug is adopted in India.